Pharmacogenomics of cisplatin-based chemotherapy in ovarian-cancer patients from Yakutia

A DNA polymorphism is one of the most important factors determining individual variations in patients’ responses to the same medicinal preparations. This work deals with assessment of associations between polymorphisms of 106 genes involved in key processes of cellular activity (xenobiotic metabolis...

Full description

Saved in:
Bibliographic Details
Published in:Molecular genetics, microbiology and virology microbiology and virology, 2013-10, Vol.28 (4), p.137-140
Main Authors: Khokhrin, D. V., Khrunin, A. V., Ivanova, F. G., Moisseev, A. A., Gorbunova, V. A., Limborska, S. A.
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Cancer Proteomics
Life Sciences
Microbiology
Molecular Medicine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A DNA polymorphism is one of the most important factors determining individual variations in patients’ responses to the same medicinal preparations. This work deals with assessment of associations between polymorphisms of 106 genes involved in key processes of cellular activity (xenobiotic metabolism, DNA repair, the cell cycle, and the regulation of apoptosis) and the outcomes of a cisplatin-based chemotherapy in a cohort of ovarian-cancer patients from Yakutia. The CDKN1B gene polymorphism (rs34330) has been found to be associated with the frequency of complete remissions. The allelic status of this locus was also shown to be significant for progression-free survival. The allelic status at the EPXH1 gene loci (rs2234922 and rs2260863) correlated with impairments in hearing, while the NBN gene polymorphism (rs1063045) was associated with severe emesis.
ISSN:0891-4168
1934-841X
DOI:10.3103/S0891416813040034